Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 16/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL946097 | 0.99 | ADORA1 (0.66) | ADORA1ADORA2AADORA3ADORA2BIKBKB | |
| SCHEMBL946132 | 0.90 | ADORA1 (0.81) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL12359336 | 0.88 | ADORA1 (0.68) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL945335 | 0.88 | ADORA1 (0.77) | ADORA1ADORA2AADORA3ADORA2BIKBKB | |
| Hydrochloric Acid SCHEMBL950249 | 0.87 | ADORA1 (0.76) | ADORA1ADORA2AADORA3ADORA2BIKBKB | |
| SCHEMBL950184 | 0.87 | ADORA1 (0.73) | ADORA1ADORA2AADORA3ADORA2BIKBKB | |
| SCHEMBL945445 | 0.87 | ADORA1 (0.73) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL12359397 | 0.86 | ADORA1 (0.68) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL411493 | 0.86 | ADORA1 (0.65) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL410912 | 0.86 | ADORA1 (0.67) | ADORA1ADORA2AADORA3ADORA2BPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989446-B2 | 4-amino 5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | claimed |
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-01-13 | — | — | US | claimed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.